Contemplating the Future of List Prices
What execs and experts think of the future of drug costs.
SUBSCRIBE: Print / Digital / eNewsletter
What execs and experts think of the future of drug costs.
Fifth company warned about unsubstantiated claims this year.
New formulation improves safety for patients.
Approved in May 2019, granted to FoldRx, a subsidiary of Pfizer.
Previously approved for IV infusion.
Fourth indication expansion for the 2009 drug.
What to expect for these high-dollar drugs.
Reduces risk for heart failure and cardiovascular disease hospitalizations.
Drug able to treat 18,000 people will cost over $300k per year.
Drug shortages might be decreasing, but their continued existence is urging the pharmacy industry to maintain its vigilance.
We've noticed that you're using an ad blocker
Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.